SEP 13, 2017 09:00 AM SGT
WEBINAR: A Case Study Review on Large-scale Manufacturing of Stem Cell Therapies
SPONSORED BY: TERUMO BCT
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
5 19 1133

Speakers:
  • Development and Project Manager MaSTherCell (Gosselies, Belgium)
    Biography
      After receiving a master's degree at the Université Louis-Pasteur in France, Amel Tounsi obtained her PhD in Immunology and Cellular Biology at UCL (Université catholique de Louvain) in Brussels. She then followed a post-doctoral fellowship at a German cancer research center where she worked on the establishment of in vivo models in mice to study the immune-regulatory activity of bone-marrow-derived mesenchymal stem cells. After her academic experience, she joined the research and development (R&D) department of Cardio3 Biosciences (now called Celyad), a Belgian biotech company developing a stem cell therapy for the treatment of chronic heart failure. Amel was involved in process improvement and developed release and potency assays. Her expertise in academia, R&D and the biotech industry was an asset for MaSTherCell, where she has worked as development and project manager since August 2014.

    Abstract:

    DATE: September 13, 2017 
    TIME:  9:00AM SGT 12:00PM AEDT

    OR

    DATE: September 12, 2017
    TIME: 6:00PM PDT

     

    To transform the promises of cell-based therapies into reality, a robust and scalable process is required to be compliant with cGMP regulations. From clinical to commercial manufacturing, processes need to produce progressively larger batches with consistent product quality. By accomplishing these processes, it can make affordable and sustainable therapies reach the market more quickly. Here we present a case study from the large scale development expansion of a process using human stem cells obtained from adult bone marrow.

    Learning Objectives:

    • An example of a process that was used to scale out an allogeneic cell therapy, based on a comprehensive look at a case study
    • The advantage of using bioreactors for cell therapy manufacturing

     


    Show Resources
    Loading Comments...